Expand CGTX Menu
CGTX MENU

CGTX Latest Press Releases

-- April 7, 2026 --

Cognition Therapeutics to Present at Needham Virtual Healthcare Conference Globe Newswire 7:30 AM

-- March 31, 2026 --

Cognition Therapeutics CEO Issues Letter to Shareholders Globe Newswire 4:30 PM

-- March 26, 2026 --

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update Globe Newswire 7:30 AM

-- March 23, 2026 --

Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results Globe Newswire 7:30 AM

-- March 17, 2026 --

Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 Globe Newswire 7:30 AM

-- March 2, 2026 --

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis Globe Newswire 7:30 AM

-- February 5, 2026 --

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies Globe Newswire 7:30 AM

-- January 27, 2026 --

Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies Globe Newswire 7:30 AM

-- January 6, 2026 --

Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies Globe Newswire 7:30 AM

-- December 3, 2025 --

Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies Globe Newswire 7:30 AM

-- December 1, 2025 --

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference Globe Newswire 7:30 AM

-- November 20, 2025 --

Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference Globe Newswire 4:01 PM

-- November 13, 2025 --

Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer's Disease Globe Newswire 7:36 AM
Market Data Delayed 15 Minutes